MedTrace Logo

Improvement the Anti-migraine Treatment Efficacy by Tailoring the Drug to Individual's Pain Modulation Profile

NCT01470339 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-09-17

No results posted yet for this study

Summary

* To delineate brain mechanisms that subserve endogenous analgesic (EA) in the healthy state.
* To identify alterations in mechanisms supporting EA in chronic pain (migraine) and their therapeutic relevance.

Conditions

Interventions

DRUG

duloxetine

duloxetine 60mg once a day for 5 weeks

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • David Yarnitsky, professor · Rambam Health Care Campus

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470339 on ClinicalTrials.gov